WO2000001817A2 - Genes mammiferes ; transporteur du type prostaglandine de cellules dendritiques (dc-pgt), hdtea84, hsljd37r et rankl, chimiokine hcc5, proteines de desubiquitination 11 et 12 (dub11, dub12), md-1, md-2 et cycline e2, reactifs apparentes et procedes associes - Google Patents

Genes mammiferes ; transporteur du type prostaglandine de cellules dendritiques (dc-pgt), hdtea84, hsljd37r et rankl, chimiokine hcc5, proteines de desubiquitination 11 et 12 (dub11, dub12), md-1, md-2 et cycline e2, reactifs apparentes et procedes associes Download PDF

Info

Publication number
WO2000001817A2
WO2000001817A2 PCT/US1999/012366 US9912366W WO0001817A2 WO 2000001817 A2 WO2000001817 A2 WO 2000001817A2 US 9912366 W US9912366 W US 9912366W WO 0001817 A2 WO0001817 A2 WO 0001817A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
seq
sequence
primate
amino acids
Prior art date
Application number
PCT/US1999/012366
Other languages
English (en)
Other versions
WO2000001817A3 (fr
Inventor
Elizabeth Esther Mary Bates
Serge J. E. Lebecque
Erin E. Murphy
Jeanine D. Mattson
Daniel M. Gorman
Joseph A. Hedrick
Luquan Wang
Albert Zlotnik
Nicholas J. Murgolo
Jonathan R. Greene
James A. Johnston
Jose Fernando Bazan
Daniel Mahony
Emma M. Lees
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to EP99931753A priority Critical patent/EP1093516A2/fr
Priority to AU48185/99A priority patent/AU4818599A/en
Priority to JP2000558207A priority patent/JP2002519062A/ja
Priority to CA002332573A priority patent/CA2332573A1/fr
Publication of WO2000001817A2 publication Critical patent/WO2000001817A2/fr
Publication of WO2000001817A3 publication Critical patent/WO2000001817A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

L'invention concerne des gènes purifiés, provenant d'un mammifère, des réactifs apparentés à ces gènes, notamment des protéines purifiées, des anticorps spécifiques et des acides nucléiques codant ces polypeptides. L'invention concerne encore des procédés d'utilisation de ces réactifs, ainsi que des nécessaires de diagnostic. Elle caractérise enfin des gènes et des produits associés à DC-PGT (transporteur du type prostaglandine de cellules dendritiques), HDTEA84, HSLJD37R et RANKL (associés à la famille des récepteurs de TNF), chimiokine HCC5, Dub 11 et Dub 12 (protéines de désubiquitination 11 et 12), MD-1 et MD-2 (protéines possédant des propriétés de ligands de protéines présentant un motif de protéine riche en leucines (LRR)) et cycline E2.
PCT/US1999/012366 1998-07-06 1999-07-06 Genes mammiferes ; transporteur du type prostaglandine de cellules dendritiques (dc-pgt), hdtea84, hsljd37r et rankl, chimiokine hcc5, proteines de desubiquitination 11 et 12 (dub11, dub12), md-1, md-2 et cycline e2, reactifs apparentes et procedes associes WO2000001817A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99931753A EP1093516A2 (fr) 1998-07-06 1999-07-06 Genes mammiferes ; transporteur du type prostaglandine de cellules dendritiques (dc-pgt), hdtea84, hsljd37r et rankl, chimiokine hcc5, proteines de desubiquitination 11 et 12 (dub11, dub12), md-1, md-2 et cycline e2, reactifs apparentes et procedes associes
AU48185/99A AU4818599A (en) 1998-07-06 1999-07-06 Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12),md-1, md2 and cyclin e2, related reagents and methods
JP2000558207A JP2002519062A (ja) 1998-07-06 1999-07-06 哺乳動物遺伝子；樹状細胞プロスタグランジン様トランスポーター（ｄｃ−ｐｇｔ）、ｈｄｔｅａ，ｈｓｌｊｄ３７ｒおよびｒａｎｋｌ、ｈｃｃ５ケモカイン、脱ユビキチン化１１および１２（ｄｕｂ１１、ｄｕｂ１２）、ｍｄ−１、ｍｄ−２およびサイクリンｅ２、関連試薬および方法
CA002332573A CA2332573A1 (fr) 1998-07-06 1999-07-06 Genes mammiferes ; transporteur du type prostaglandine de cellules dendritiques (dc-pgt), hdtea84, hsljd37r et rankl, chimiokine hcc5, proteines de desubiquitination 11 et 12 (dub11, dub12), md-1, md-2 et cycline e2, reactifs apparentes et procedes associes

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US11093898A 1998-07-06 1998-07-06
US09/110,938 1998-07-06
US11446698A 1998-07-13 1998-07-13
US09/114,466 1998-07-13
US9389798P 1998-07-23 1998-07-23
US60/093,897 1998-07-23
US13296898A 1998-08-12 1998-08-12
US09/132,968 1998-08-12
US13621498A 1998-08-18 1998-08-18
US09/136,214 1998-08-18
US9999998P 1998-09-11 1998-09-11
US60/099,999 1998-09-11

Publications (2)

Publication Number Publication Date
WO2000001817A2 true WO2000001817A2 (fr) 2000-01-13
WO2000001817A3 WO2000001817A3 (fr) 2000-06-29

Family

ID=27557472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012366 WO2000001817A2 (fr) 1998-07-06 1999-07-06 Genes mammiferes ; transporteur du type prostaglandine de cellules dendritiques (dc-pgt), hdtea84, hsljd37r et rankl, chimiokine hcc5, proteines de desubiquitination 11 et 12 (dub11, dub12), md-1, md-2 et cycline e2, reactifs apparentes et procedes associes

Country Status (5)

Country Link
EP (1) EP1093516A2 (fr)
JP (1) JP2002519062A (fr)
AU (1) AU4818599A (fr)
CA (1) CA2332573A1 (fr)
WO (1) WO2000001817A2 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1022336A1 (fr) * 1997-10-07 2000-07-26 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
WO2000061757A1 (fr) * 1999-04-12 2000-10-19 Genentech, Inc. Homologues de facteur de necrose tumorale et acides nucleiques les codant
WO2001000821A1 (fr) * 1999-06-23 2001-01-04 Angiogene Inc. Oligonucleotides anti-sens modulant l'expression du gene de la cycline et leurs utilisations therapeutiques
WO2001021792A1 (fr) * 1999-09-21 2001-03-29 Chugai Seiyaku Kabushiki Kaisha Genes transporteurs oatp-b, c, d et e
WO2001023585A1 (fr) * 1999-09-30 2001-04-05 Millennium Pharmaceuticals, Inc. Ubiquitine-protease humaine: 23484
WO2001030850A1 (fr) * 1999-10-22 2001-05-03 Zymogenetics, Inc. Polypeptides umlr
EP1144443A3 (fr) * 1998-11-04 2001-12-05 Incyte Pharmaceuticals, Inc. Proteines de transport membranaire
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
WO2002038761A2 (fr) * 2000-11-09 2002-05-16 Bayer Aktiengesellschaft Regulation d'une proteine du type transport d'anions organiques
US6451994B1 (en) 1999-09-27 2002-09-17 Millennium Pharmaceuticals, Inc. 23413, a novel human ubiquitin protease
WO2003013583A1 (fr) * 2001-08-10 2003-02-20 Genset S.A. Agonistes et antagonistes de faxigene dans le traitement de troubles metaboliques
US6900044B2 (en) 2001-03-27 2005-05-31 Millennium Pharmaceutical, Inc. 68999, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor
EP1534825A2 (fr) * 2002-02-22 2005-06-01 Aventis Pharmaceuticals, Inc. Analogues humains de genes de protease murine liberatrice d'ubiquitine
WO2005049818A2 (fr) * 2003-11-14 2005-06-02 The Queen's University Of Belfast Gene
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
WO2005116220A1 (fr) * 2004-05-28 2005-12-08 Cambridge University Technical Services Limited Production de proteines recombinantes au moyen de prosequences heterologues
US7109306B2 (en) 1996-12-20 2006-09-19 Human Genome Sciences, Inc. Antibodies to human oncogene induced secreted protein I
EP1710299A2 (fr) * 1998-12-30 2006-10-11 Millennium Pharmaceuticals, Inc. Proteines secretées et polynucleotides codant pour ces proteines
US7179631B2 (en) 2002-03-22 2007-02-20 Aventis Pharmaceuticals Inc. Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
US7186800B1 (en) 1997-01-14 2007-03-06 Human Genome Sciences, Inc. Tumor necrosis factor 6α and 6β
US7223852B2 (en) 1997-09-12 2007-05-29 Biogen Idec Ma Inc. Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US7329529B2 (en) 1999-09-03 2008-02-12 Millennium Pharmaceuticals, Inc. Ubiqutin proteases
US7482147B2 (en) 1999-09-27 2009-01-27 Millennium Pharmaceuticals, Inc. Ubiquitin protease
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
US9757451B2 (en) 2011-11-07 2017-09-12 UNIVERSITé LAVAL Use of RANK/RANKL antagonists for treating muscular dystrophy
US10023646B2 (en) 2003-12-10 2018-07-17 NovImmunie S.A. Neutralizing antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017092A1 (fr) * 1993-12-22 1995-06-29 Human Genome Sciences, Inc. PROTEINES-3, -4 ET 1η INFLAMMATOIRES MACROPHAGES
WO1996034891A1 (fr) * 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017092A1 (fr) * 1993-12-22 1995-06-29 Human Genome Sciences, Inc. PROTEINES-3, -4 ET 1η INFLAMMATOIRES MACROPHAGES
WO1996034891A1 (fr) * 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
D.L. LACEY ET AL.: "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation." CELL, vol. 93, 17 April 1998 (1998-04-17), pages 165-176, XP002125264 cited in the application *
HOCHSTRASSER M: "UBIQUITIN, PROTEASOMES, AND THE REGULATION OF INTRACELLULAR PROTEINDEGRADATION" CURRENT OPINION IN CELL BIOLOGY,GB,CURRENT SCIENCE, LONDON, vol. 7, no. 2, page 215-223 XP000670260 ISSN: 0955-0674 cited in the application *
K. MIYAKE ET AL.: "Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression." THE JOURNAL OF IMMUNOLOGY, vol. 161, 1998, pages 1348-1353, XP002125265 cited in the application *
LEW D J ET AL: "ISOLATION OF THREE NOVEL HUMAN CYCLINS BY RESCUE OF G1 CYCLIN (CLN) FUNCTION IN YEAST" CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 66, 20 September 1991 (1991-09-20), page 1197-1206 XP002039130 ISSN: 0092-8674 cited in the application *
LODI P J ET AL: "HIGH-RESOLUTION SOLUTION STRUCTURE OF THE BETA CHEMOKINE HMIP-1BETABY MULTIDIMENSIONAL NMR" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 263, page 1762-1767 XP002054455 ISSN: 0036-8075 cited in the application *
N. KANAI ET AL.: "Identification and characterization of a Prostaglandin transporter." SCIENCE, vol. 268, 12 May 1995 (1995-05-12), pages 866-869, XP002125266 cited in the application *
NAGASE ET AL: "Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro" DNA RESEARCH,JP,UNIVERSAL ACADEMY PRESS, vol. 5, no. 5, page 355-364-64 XP002111974 ISSN: 1340-2838 *
R. LU ET AL.: "Cloning, In vitro expression, and tissue distribution of a human Prostaglandin transporter cDNA (hPGT)." THE JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 5, 1 September 1996 (1996-09-01), pages 1142-1149, XP000863207 cited in the application *
R. LU ET AL.: "Molecular cloning of the gene for human Prostaglandin Transporter hPGT: gene organization, promoter activity, and chromosomal localization." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 246, 1998, pages 805-812, XP002125267 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109306B2 (en) 1996-12-20 2006-09-19 Human Genome Sciences, Inc. Antibodies to human oncogene induced secreted protein I
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US8003386B1 (en) 1997-01-14 2011-08-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
US7186800B1 (en) 1997-01-14 2007-03-06 Human Genome Sciences, Inc. Tumor necrosis factor 6α and 6β
US7709218B2 (en) 1997-01-14 2010-05-04 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
US7534428B2 (en) 1997-01-14 2009-05-19 Human Genome Sciences, Inc. Antibodies to tumor necrosis factor receptors 6α and 6β
US6358508B1 (en) 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6919078B2 (en) 1997-06-11 2005-07-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US7776560B2 (en) 1997-06-11 2010-08-17 Human Genome Scienes, Inc. Human tumor necrosis factor receptor TR9 antibody
US7402658B2 (en) 1997-09-12 2008-07-22 Biogen Idec Ma Inc. TRAIN-R: a cysteine-rich member of the TNF-receptor family
US7223852B2 (en) 1997-09-12 2007-05-29 Biogen Idec Ma Inc. Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family
US7838639B2 (en) 1997-09-12 2010-11-23 Biogen Idec Ma Inc. Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
EP1022336A1 (fr) * 1997-10-07 2000-07-26 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
EP1022336A4 (fr) * 1997-10-07 2003-06-04 Ono Pharmaceutical Co POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
EP1144443A3 (fr) * 1998-11-04 2001-12-05 Incyte Pharmaceuticals, Inc. Proteines de transport membranaire
EP1710299A3 (fr) * 1998-12-30 2007-01-10 Millennium Pharmaceuticals, Inc. Proteines secretées et polynucleotides codant pour ces proteines
EP1710299A2 (fr) * 1998-12-30 2006-10-11 Millennium Pharmaceuticals, Inc. Proteines secretées et polynucleotides codant pour ces proteines
US6534061B1 (en) 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
JP2002541806A (ja) * 1999-04-12 2002-12-10 ジェネンテック・インコーポレーテッド 腫瘍壊死因子相同体及びそれをコードする核酸
WO2000061757A1 (fr) * 1999-04-12 2000-10-19 Genentech, Inc. Homologues de facteur de necrose tumorale et acides nucleiques les codant
US7198913B2 (en) 1999-04-12 2007-04-03 Genentech, Inc. Nucleic acids encoding a tumor necrosis factor homolog
WO2001000821A1 (fr) * 1999-06-23 2001-01-04 Angiogene Inc. Oligonucleotides anti-sens modulant l'expression du gene de la cycline et leurs utilisations therapeutiques
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
US7329529B2 (en) 1999-09-03 2008-02-12 Millennium Pharmaceuticals, Inc. Ubiqutin proteases
US8748128B2 (en) 1999-09-21 2014-06-10 Chugai Seiyaku Kabushiki Kaisha Transporter genes OATP-B, C, D, and E
JP4838961B2 (ja) * 1999-09-21 2011-12-14 中外製薬株式会社 トランスポーター遺伝子ｏａｔｐ−ｂ、ｃ、ｄ、およびｅ
WO2001021792A1 (fr) * 1999-09-21 2001-03-29 Chugai Seiyaku Kabushiki Kaisha Genes transporteurs oatp-b, c, d et e
US7045316B2 (en) 1999-09-21 2006-05-16 Chugai Seiyaku Kabushiki Kaisha Transporter genes OATP-B,C,D, and E
US7776577B2 (en) 1999-09-27 2010-08-17 Millennium Pharmaceuticals, Inc. Ubiquitin protease
US7482147B2 (en) 1999-09-27 2009-01-27 Millennium Pharmaceuticals, Inc. Ubiquitin protease
US6451994B1 (en) 1999-09-27 2002-09-17 Millennium Pharmaceuticals, Inc. 23413, a novel human ubiquitin protease
US6329171B1 (en) 1999-09-30 2001-12-11 Millennium Pharmaceuticals, Inc. 23484, A novel human ubiquitin protease
WO2001023585A1 (fr) * 1999-09-30 2001-04-05 Millennium Pharmaceuticals, Inc. Ubiquitine-protease humaine: 23484
US7217790B2 (en) 1999-10-22 2007-05-15 Zymogenetics, Inc. UMLR polypeptides
WO2001030850A1 (fr) * 1999-10-22 2001-05-03 Zymogenetics, Inc. Polypeptides umlr
WO2002038761A2 (fr) * 2000-11-09 2002-05-16 Bayer Aktiengesellschaft Regulation d'une proteine du type transport d'anions organiques
WO2002038761A3 (fr) * 2000-11-09 2004-01-08 Bayer Ag Regulation d'une proteine du type transport d'anions organiques
US6900044B2 (en) 2001-03-27 2005-05-31 Millennium Pharmaceutical, Inc. 68999, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor
WO2003013583A1 (fr) * 2001-08-10 2003-02-20 Genset S.A. Agonistes et antagonistes de faxigene dans le traitement de troubles metaboliques
EP1534825A2 (fr) * 2002-02-22 2005-06-01 Aventis Pharmaceuticals, Inc. Analogues humains de genes de protease murine liberatrice d'ubiquitine
EP1534825A4 (fr) * 2002-02-22 2006-02-01 Aventis Pharma Inc Analogues humains de genes de protease murine liberatrice d'ubiquitine
US7179631B2 (en) 2002-03-22 2007-02-20 Aventis Pharmaceuticals Inc. Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
WO2005049818A3 (fr) * 2003-11-14 2006-01-05 Univ Belfast Gene
WO2005049818A2 (fr) * 2003-11-14 2005-06-02 The Queen's University Of Belfast Gene
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US20140314769A1 (en) * 2003-12-10 2014-10-23 Novimmune S.A. Neutralizing Antibodies And Methods Of Use Thereof
US9534049B2 (en) * 2003-12-10 2017-01-03 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US20170107296A1 (en) * 2003-12-10 2017-04-20 Novimmune Sa Neutralizing Antibodies and Methods of Use Thereof
US10023646B2 (en) 2003-12-10 2018-07-17 NovImmunie S.A. Neutralizing antibodies and methods of use thereof
US10844132B2 (en) 2003-12-10 2020-11-24 Novimmune Sa Neutralizing antibodies and methods of use thereof
WO2005116220A1 (fr) * 2004-05-28 2005-12-08 Cambridge University Technical Services Limited Production de proteines recombinantes au moyen de prosequences heterologues
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
US9757451B2 (en) 2011-11-07 2017-09-12 UNIVERSITé LAVAL Use of RANK/RANKL antagonists for treating muscular dystrophy

Also Published As

Publication number Publication date
AU4818599A (en) 2000-01-24
WO2000001817A3 (fr) 2000-06-29
EP1093516A2 (fr) 2001-04-25
CA2332573A1 (fr) 2000-01-13
JP2002519062A (ja) 2002-07-02

Similar Documents

Publication Publication Date Title
EP1093516A2 (fr) Genes mammiferes ; transporteur du type prostaglandine de cellules dendritiques (dc-pgt), hdtea84, hsljd37r et rankl, chimiokine hcc5, proteines de desubiquitination 11 et 12 (dub11, dub12), md-1, md-2 et cycline e2, reactifs apparentes et procedes associes
US6512103B1 (en) Mammalian chemokine reagents
US20060025572A1 (en) Mammalian cell surface antigens; related reagents
WO1998027114A2 (fr) Antigenes de surface mammaliens et reactifs associes
EP1115867A1 (fr) Interleukine humaine b50, ses utilisations therapeutiques
WO2000073451A1 (fr) Proteines de recepteur mammaliennes, reactifs et procedes y relatifs
US20100068763A1 (en) Mammalian chemokines; receptors; reagents; uses
WO1997029192A1 (fr) Reactifs constitues d'une chemokine de cellules dendritiques de mammiferes
US20100261190A1 (en) Mammalian Genes; Related Reagents and Methods
US20030028005A1 (en) Mammalian proteins; related reagents and methods
CA2356661A1 (fr) Agonistes ou antagonistes de la chemokine d'attraction des lymphocytes t (ctack) ou des chemokines des contracteurs intestinaux vasoactifs (vic)
EP1240183A2 (fr) Genes de mammifere, reactifs associes et procedes
US20020143147A1 (en) Mammalian genes; related reagents
MXPA01000308A (en) Mammalian genes;dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods
CA2163105A1 (fr) Ligands flt3 purifies de mammiferes; agonistes et antagonistes de ces ligands
WO1997029125A1 (fr) Reactifs constitues de chemokine de cellules dendritiques de mammiferes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 558207

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999931753

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2332573

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000308

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999931753

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999931753

Country of ref document: EP